Out of the 25 genes identified in our study, multiple have been implicated in cancer and may be targetable, including MAP2K4 in prostate cancer (17), ID2 in glioma (18), JAK1 in multiple cancer types (19), FGF2 to address resistance to anti-VEGF therapy (20), PIK3R1 and AKT3 using PI3K/AKT/mTOR inhibitors (21), FGF13 which mediates resistance to platinum therapy in cervical cancer (22), and STAT3 which has also been proposed as a target in cervical cancer (23). This evidence concerns the gene AKT1 and Familial prostate cancer.